التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment. |
| المؤلفون: |
Palanques-Pastor, Tomás, Megías-Vericat, Juan Eduardo, Bosó Ribelles, Virginia, Gómez Seguí, Inés, Poveda Andrés, José Luis |
| المصدر: |
Acta Haematologica; Jan2022, Vol. 145 Issue 1, p72-77, 6p |
| مصطلحات موضوعية: |
THROMBOTIC thrombocytopenic purpura, THROMBOPENIC purpura, VON Willebrand factor, PLATELET count, THROMBOSPONDIN-1 |
| مستخلص: |
Acquired thrombocytopenic thrombotic purpura (aTTP) is an autoantibody-mediated disease against the enzyme A Disintegrin and Metalloprotease domain with ThromboSpondin-1 type motif 13, which until now has been treated with plasma exchange (PEX) and corticosteroids. A 29-year-old female patient, who presented with aTTP in the context of pregnancy, has developed multiple relapses after treatment with PEX, corticosteroids, and rituximab. Recently, caplacizumab, a nanobody against von Willebrand factor, has been approved for the treatment of aTTP. In our patient, caplacizumab achieved better disease control, with a lower platelet count restoration time, days of PEX and hospitalization duration, as compared to standard therapy, reproducing the results of clinical trials. Caplacizumab represents a significant advance in the treatment of aTTP, especially in cases of recurrent relapses. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Haematologica is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
